SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bombay HC upholds compulsory license granted to Natco Pharma on Nexavar

16 Jul 2014 Evaluate

The Bombay High Court has upheld the compulsory license (CL) granted Natco Pharma on Nexavar (sorafenib tosylate) of German drug major Bayer’s patented kidney cancer drug.

The Nexavar issue dates back to March 9, 2012, when the then Controller General of Patents issued the first-ever CL to the company to manufacture an affordable generic version of sorafenib tosylate, the anti-cancer drug for which Bayer had obtained a patent.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1113.35 -5.60 (-0.50%)
20-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.10
Dr. Reddys Lab 1238.25
Cipla 1238.70
Zydus Lifesciences 941.50
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×